80 results
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
7 May 24
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:11pm
will include:
Initial safety and efficacy data on the first 30 patients enrolled in dose expansion
Updated safety and efficacy data on the 7 dose … will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates or that clinical outcomes may differ as patient
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
Item 3. Legal Proceedings 106 Item 4. Mine Safety Disclosures 106 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters … or prevented. Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates and if this happens
8-K
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
data will not ultimately be predictive of the safety and efficacy of the Company’s product candidates or that clinical outcomes may differ as patient
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases … by year-end 2024.
“CB-010 has demonstrated encouraging initial safety and efficacy in patients with relapsed or refractory B cell non-Hodgkin
8-K
EX-99.2
32m7yw1
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
8-K
EX-99.1
jztrqv5a4ia8b11j
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
8-K
EX-99.1
shenmdfz j643rjegza
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
0e3mkz
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
mg420vm4
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
EX-99.1
l9mch4gqs g20wd40z
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
EX-99.1
rzynpt
7 Nov 23
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
eo91p2
18 Oct 23
Regulation FD Disclosure
8:02am
8-K
EX-99.1
fseklmb8va6
8 Aug 23
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
EX-1.1
yvz1ivl fb7xv
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
tiiq qtqcf
14 Jul 23
Prospectus supplement for primary offering
5:31pm